• PNS321 EASINESS AND RELIABILITY IN ESTIMATING PATIENT-LEVEL SURVIVAL DATA FROM KAPLAN-MEIER CURVES

    Nov 1, 2019, 00:00

  • PUK20 ECONOMIC EVALUATION OF CILOSTAZOL IN COMPARISON WITH PENTOXIFYLLINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION IN IRAN

    Nov 1, 2019, 00:00

  • PCV62 ECONOMIC EVALUATION AND NETWORK META-ANALYSIS OF NON-STATIN THERAPY AMONG STATIN-TREATED PATIENTS IN THAILAND

    Nov 1, 2019, 00:00

  • Artificial Intelligence Studies

    Nov 1, 2019, 00:00

  • PRO6 TRANSLATION AND LINGUISTIC VALIDATION OF THE HEMOPHILIA QUALITY OF LIFE (HAEMO-QOL-A) QUESTIONNAIRE FOR USE WITH HEMOPHILIA PATIENTS

    Nov 1, 2019, 00:00

  • PCN307 IMPROVING PATIENT ACCESS TO PD-(L)1 THERAPIES IN CHINA: POLICY IMPLICATIONS FROM PREVIOUS NRDL NEGOTIATIONS

    Nov 1, 2019, 00:00

  • Drugs Information Systems

    Nov 1, 2019, 00:00

  • PMH37 COMPARING THE QUALITY OF SLEEP AMONGST BENZODIAZEPINE DEPRESCRIBED GROUP AND CONTINUING GROUP

    Nov 1, 2019, 00:00

  • PNS122 LONG-ACTING GENE THERAPIES: CURRENT DEVELOPMENT ACTIVITIES AND CHALLENGES FOR GERMANY'S STATUTORY HEALTH INSURANCE SYSTEM

    Nov 1, 2019, 00:00

  • PCV82 ATHEROSCLEROSIS: BURDEN OF DISEASE IN PORTUGAL

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PNS43 ORGANISING THE LITERATURE IN A SYSTEMATIC LITERATURE REVIEW USING FACTOR ANALYSIS

    Nov 1, 2019, 00:00

  • PNS224 SHOULD THE PATIENT VOICE HAVE AN ACTIVE ROLE IN HTA DECISION-MAKING? A PAG CONSENSUS ANALYSIS IN GREECE

    Nov 1, 2019, 00:00

  • PCV47 DOES THE COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN COMBINATION WITH STATIN THERAPY COMPARED TO STATIN ALONE DIFFER BETWEEN PRIMARY AND SECONDARY PREVENTION?

    Nov 1, 2019, 00:00

  • PCN257 CERVICAL CANCER INCIDENCE IN A POPULATION OF 41,202 WOMEN SCREENED BY CONVENTIONAL CYTOLOGY AT A SINGLE PRIVATE LABORATORY OF SOUTHEAST BRAZIL

    Nov 1, 2019, 00:00

  • PCV116 USING ADMINISTRATIVE CLAIMS DATA TO ESTIMATE THERAPEUTIC INTENSITY IN MEDICALLY MANAGED HEART FAILURE PATIENTS

    Nov 1, 2019, 00:00

  • PRO156 APPROACHES TO THE COLLECTION OF UTILITY VALUES FOR RARE DISEASES

    Nov 1, 2019, 00:00

  • Cardiovascular Diabetes Disorder Studies

    Nov 1, 2019, 00:00

  • PCN451 MODELING THE SURVIVAL BENEFIT OF IMMUNO-ONCOLOGIC THERAPY: A REVIEW OF METHODS USED IN NICE SINGLE TECHNOLOGY APPRAISALS

    Nov 1, 2019, 00:00

  • PBI23 A COST ANALYSIS OF HEMOSTATIC SURGICAL RESOURCES ASSOCIATED WITH A NOVEL FIBRIN SEALANT COMPARED TO STANDARD OF CARE ACROSS SURGERY TYPES

    Nov 1, 2019, 00:00

  • PMS14 FLARE QUESTIONNAIRE FOR RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND RECURRENCE IDENTIFICATION IN CLINICAL RESEARCH

    Nov 1, 2019, 00:00

  • PNS395 PATIENT-REPORTED OUTCOME INSTRUMENTS IN ARABIC-SPEAKING POPULATIONS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PNS54 FACIAL DRUG PRICES REGULATION BETWEEN 2011 AND 2018 IN FRANCE

    Nov 1, 2019, 00:00

  • PCN155 AN ECONOMIC SYSTEMATIC LITERATURE REVIEW FOR UNTREATED ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) NON-SMALL-CELL LUNG CANCER (NSCLC)

    Nov 1, 2019, 00:00

  • PMS15 REAL-WORLD EFFECTIVENESS OF SECUKINUMAB FOR PSORIATIC ARTHRITIS PATIENTS: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN

    Nov 1, 2019, 00:00

  • PND91 APPLICATION OF BIG DATA IN RARE DISEASE MANAGEMENT: TREATMENT COST OF THERAPEUTIC PLASMA EXCHANGE VERSUS IMMUNOGLOBULINS IN AN INPATIENT SETTING

    Nov 1, 2019, 00:00

  • PNS268 AGGREGATING MULTIPLE ENDPOINTS/PERFORMANCE INDICATORS TO CALCULATE A UNIDIMENSIONAL MEASUREMENT OF VALUE IN A COMPOSITE INDEX

    Nov 1, 2019, 00:00

  • PRO82 REIMBURSEMENT AND PRICING OF ORPHAN DRUGS IN TAIWAN

    Nov 1, 2019, 00:00

  • PIN119 NOVEL PRICING OF NEW ANTIMICROBIALS – HOW CAN WE PRICE TO REFLECT THE VALUE TO SOCIETY AND THE MANUFACTURER?

    Nov 1, 2019, 00:00

  • PMD43 EFFICACY AND SAFETY OF MECHANICAL THROMBECTOMY IN PATIENTS WITH ISCHEMIC STROKE: AN UMBRELLA SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PBI86 INVESTIGATION ON THE CURRENT STATUS SURROUNDING BIOLOGICS AND THE IMPACT OF BIOSIMILARS USING JAPANESE REAL-WORLD DATA IN FY2017

    Nov 1, 2019, 00:00

  • PNS253 IS THERE STILL A REASON TO ARGUE FOR HIGHER DECISION-MAKING EFFICIENCY WITH SINATS? UPDATED ANALYSIS

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PCN91 COST-EFFECTIVENESS OF IMMUNOTHERAPY-BASED DRUG REGIMENS FOR THE INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PNS299 THE INCREASING USE AND ACCEPTANCE OF ALTERNATIVE STATISTICAL APPROACHES TO INDIRECT COMPARISON IN THE NATIONAL INSTITUTE OF HEALTH AND CARE EXCELLENCE (NICE) HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSION PROCESS

    Nov 1, 2019, 00:00

  • PIH55 A MULTIVARIATE APPROACH TO EXPLORE THE DRIVERS OF MEDICINE ACCEPTABILITY IN PEDIATRICS

    Nov 1, 2019, 00:00

  • PIH37 ASSESSMENT OF PRECLINICAL MARKERS "MOBILITY LIMITATIONS” AND "COGNITIVE IMPAIRMENT” AMONG GERIATRIC INPATIENTS: EVIDENCE FROM THE CROSS SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PRS36 EPIDEMIOLOGICAL AND CLINICAL FEATURES OF HMPV AND RSV INFECTIONS AMONG CHILDREN HOSPITALIZED FROM ACUTE RESPIRATORY INFECTIONS IN MACAO: A RETROSPECTIVE STUDY FROM 2014 TO 2017

    Nov 1, 2019, 00:00

  • PCV33 COST-EFFECTIVENESS OF WEARABLE CARDIOVERTER-DEFIBRILLATOR IN CHINA: A DECISION ANALYSIS

    Nov 1, 2019, 00:00

  • PIN110 HEALTH AND ECONOMIC IMPACT OF 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPES IN ADULTS 65 YEARS AND OLDER IN 5 EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PNS325 GAME THEORY IN THE HEALTHCARE LITERATURE:A SYSTEMATIC REVIEW FOCUSING ON NEGOTIATIONS

    Nov 1, 2019, 00:00

  • PDB54 ECONOMIC EVALUATION OF A NEW POLYGENIC RISK SCORE TO PREVENT NEPHROPATHIES IN TYPE-2 DIABETIC PATIENTS

    Nov 1, 2019, 00:00

  • PCN479 PATIENT-REPORTED SYMPTOM BURDEN OF CHRONIC GRAFT VERSUS HOST DISEASE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE

    Nov 1, 2019, 00:00

  • PBI2 COMPARISON OF A NEW FIBRIN SEALANT TO CURRENT HEMOSTASIS METHODS IN PERIPHERAL VASCULAR SURGERY: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • PGI14 PHARMACOECONOMIC ASPECTS OF TREATMENT OF ACUTE PANCREATIS IN CENTRAL PART OF SERBIA - COST OF ILLNESS STUDY BASED ON DATA FROM TERTIARY REFERRAL HOSPITAL

    Nov 1, 2019, 00:00

  • PCV32 COST ANALYSIS OF REIMBURSED SPENDING ON ACE-INHIBITORS AND SARTANS IN BULGARIA

    Nov 1, 2019, 00:00

  • Neurological Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PNS131 DO THE EVOLVING MARKET ACCESS POLICY DYNAMICS AND INCREASING IMPORTANCE OF CLINICAL AND HEALTH ECONOMIC EVIDENCE REPRESENT THE NEXT BIG OPPORTUNITY FOR PHARMA TO DEMONSTRATE VALUE IN CHINA?

    Nov 1, 2019, 00:00

  • PND56 BUDGET IMPACT ANALYSIS OF INCLUSION IN THE PUBLIC FINANCING OCRELIZUMAB THERAPY FOR PRIMARY-PROGREDIENT AND HIGHLY ACTIVE REMITTING FORMS OF MULTIPLE SCELEROSIS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PCN502 RETROSPECTIVE GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY HEALTH INSURANCE)] STUDY ON INITIAL TREATMENT OF BLADDER CARCINOMA (BCA) BY TRANSURETHRAL BLADDER RESECTION (TURB) - A COMPARATIVE ANALYSIS OF COSTS AND UROLOGICAL FOLLOW- ...

    Nov 1, 2019, 00:00

  • PCN270 AVAILABILITY OF EARLY PREVENTION AND TARGETED THERAPY FOR BRCA-ASSOSIATED PATIENTS WITH BREAST AND/OR OVARIAN CANCER

    Nov 1, 2019, 00:00

  • PMH21 COST-EFFECTIVENESS OF THE PREDICT TEST: RESULTS AND LESSONS LEARNED FROM A EUROPEAN MULTINATIONAL DEPRESSION TRIAL

    Nov 1, 2019, 00:00

  • PCV8 EFFICACY OF VENOUS EXERCISE FOR THE CHANGE OF VENOUS FLOW VELOCITY AMONG PREGNANT WOMEN

    Nov 1, 2019, 00:00

  • PMS54 FRACTURE LIAISON SERVICES

    Nov 1, 2019, 00:00

  • PCN527 US HEALTHCARE DATABASES FOR HEALTH ECONOMIC MODELING IN PRECISION MEDICINE: AN ONCOLOGY-BASED COMPARATIVE LANDSCAPE ASSESSMENT

    Nov 1, 2019, 00:00

  • PMS25 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE KNEE AND LOWER LEG IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PBI78 CAR-T TREATMENTS: INSIGHTS FROM INITIAL HEALTH TECHNOLOGY ASSESSMENT DECISIONS IN THE UK, GERMANY AND FRANCE

    Nov 1, 2019, 00:00

  • Cost-Effectiveness Studies

    Nov 1, 2019, 00:00

  • PMU72 ATTRIBUTES OF DISSATISFACTION OF HEALTH INSURANCE COVERAGE IN PATIENTS VISITED PUBLIC AND PRIVATE DENTAL HEALTHCARE CENTERS

    Nov 1, 2019, 00:00

  • PMH65 COMPARISON OF CHARACTERISTICS AND MEDICATION-ASSISTED TREATMENT (MAT)-RELATED HEALTHCARE RESOURCE UTILIZATION AMONG US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY TYPE OF MAT RECEIVED

    Nov 1, 2019, 00:00

  • ND4 WHO BENEFITS MOST FROM COLLABORATIVE DEMENTIA CARE? A POST-HOC SUBGROUP COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2019, 00:00

  • PMU133 TRANSLATION AND CULTURAL ADAPTATION OF 15D QUALITY OF LIFE QUESTIONNAIRE FROM ENGLISH TO ROMANIAN LANGUAGE

    Nov 1, 2019, 00:00

  • PNS277 THE ROLE OF EARLY VALUE FRAMEWORK IN A SUCCESSFUL REIMBURSEMENT JOURNEY

    Nov 1, 2019, 00:00

  • PNS181 SUBMISSIONS TO A NATIONAL HTA AGENCY IN IRELAND: DRUGS WITH DESIGNATED ORPHAN STATUS

    Nov 1, 2019, 00:00

  • PNS166 WHICH FACTORS INFLUENCE PRICING DECISION WHEN A NEW INDICATION ARRIVES?

    Nov 1, 2019, 00:00

  • PNS207 CANCER-RELATED HEALTH TECHNOLOGY ASSESSMENT (HTA) OUTCOMES BY EUROPEAN HTA AGENCIES: A COMPARATIVE ANALYSIS OF G-BA, HAS AND NICE

    Nov 1, 2019, 00:00

  • PMS64 ASSESSING THE QUALITY OF BIOLOGIC SWITCH DECISIONS IN PSORIATIC ARTHRITIS: VALIDATION OF PASQAL - AN OUTCOMES MEASUREMENT TOOL

    Nov 1, 2019, 00:00

  • NO Specific Disease - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PIH5 USING ARTIFICIAL REPRODUCTIVE DATABASE TO ESTABLISH PREDICTED PROBABILISTIC MODEL OF A SUCCESS LIVE BIRTH AFTER IN VITRO FERTILIZATION

    Nov 1, 2019, 00:00

  • PSY14 A LITERATURE REVIEW TO IDENTIFY, CRITIQUE AND SELECT THE MOST SUITABLE ECONOMIC MODEL FOR USE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) UK HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS

    Nov 1, 2019, 00:00

  • PRS44 CHARACTERISTICS OF MEDICARE ADVANTAGE BENEFICIARIES INITIATING LONG-ACTING MUSCARINIC ANTAGONISTS (LAMA) USING DRY POWDER OR SOFT MIST INHALERS

    Nov 1, 2019, 00:00

  • PCV102 PRESCRIPTION PATTERN EUROPE

    Nov 1, 2019, 00:00

  • PDB77 WILSON'S DISEASE: COST OF HOSPITALIZATION IN GERMANY

    Nov 1, 2019, 00:00

  • PSY32 DELAY IN DIAGNOSIS OF PRIMARY LYMPHOEDEMA AND ITS IMPACT ON QUALITY OF LIFE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PIN67 BUDGET IMPACT ANALYSIS OF THE IMPLEMENTATION OF A PRESURGICAL WARMING PROTOCOL TO EFFECTIVELY MANAGE SURGICAL PATIENT NORMOTHERMIA

    Nov 1, 2019, 00:00

  • PMS27 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE HIP AND THIGH IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PDB25 COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN

    Nov 1, 2019, 00:00

  • PBI15 ECONOMIC BURDEN OF SICKLE CELL DISEASE: A TARGETED GLOBAL LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN212 ECONOMIC EVALUATION OF TOPOTECAN IN COMPARISON WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN THE TREATMENT OF RECURRENT OVARIAN CANCER IN IRAN

    Nov 1, 2019, 00:00

  • PRO137 PATIENT CHARACTERISTICS ASSOCIATED WITH GREATER HIDRADENITIS SUPPURATIVA SEVERITY AGREEMENT BETWEEN PATIENT AND CLINICIAN GLOBAL ASSESSMENTS

    Nov 1, 2019, 00:00

  • PCN457 THE SISAQOL INITIATIVE: ESTABLISHING INTERNATIONAL STANDARDS AND RECOMMENDATIONS FOR THE ANALYSIS OF PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE DATA IN ONCOLOGY RANDOMIZED CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • PCV15 POTENTIAL IMPACT OF PROLONGED DUAL ANTIPLATELET THERAPY WITH TICAGRELOR IN 'REAL WORLD' STABLE PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION VERSUS RANDOMIZED CONTROLLED TRIAL POPULATIONS

    Nov 1, 2019, 00:00

  • PNS56 EVALUATION OF THE IMPACT OF ALTERNATIVE DRUG PRICING STRATEGIES USED ON THE BUDGET IMPACT AND COST-EFFECTIVENESS FOR PRODUCTS WITH MULTIPLE INDICATIONS

    Nov 1, 2019, 00:00

  • PND95 PRODUCTIVITY LOSS COST IN MIGRAINE USING TWO DIFFERENT QUESTIONNAIRES: FINDINGS FROM THE BECOME STUDY FOR PORTUGAL

    Nov 1, 2019, 00:00

  • PCN21 TREATMENT COMPARISONS IN PATIENTS WITH UNRESECTABLE HEPTOCELLULAR CARCINOMA (HCC) WHO ARE INELIGIBLE FOR TRANSARTERIAL CHEMOEMBOLISATION (TACE)

    Nov 1, 2019, 00:00

  • PNS376 EQUIVALENCE OF ONLINE METHODS TO ASSESS CONTENT VALIDITY

    Nov 1, 2019, 00:00

  • PNS406 BURDEN OF POST-TRANSPLANT OUTCOMES AFTER LIVER TRANSPLANTATION IN SOUTH KOREA: KOREAN ORGAN TRANSPLANTATION REGISTRY (KOTRY) ANALYSIS STUDY

    Nov 1, 2019, 00:00

  • PNS127 THE DEVELOPMENT OF CHIMERIC ANTIGEN RECEPTOR (CAR-T) CELL THERAPY IN CHINA

    Nov 1, 2019, 00:00

  • PMS30 SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE TURKISH PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PDB64 COST-EFFECTIVENESS OF CANAGLIFLOZIN TREATMENT IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND KIDNEY DISEASE

    Nov 1, 2019, 00:00

  • PCN261 ESTIMATING THE NUMBER OF PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE ACROSS EUROPE

    Nov 1, 2019, 00:00

  • PCV75 COST ANALYSIS OF COMPLICATIONS WITH CORONARY ARTERY DISEASE OR PERIPHERAL ARTERY DISEASE IN TURKEY

    Nov 1, 2019, 00:00

  • PCN88 HOW ARE WE ASSESSING THE VALUE FOR MONEY OF CANCER BIOMARKERS IN ECONOMIC EVALUATIONS?

    Nov 1, 2019, 00:00

  • PBI76 EVOLUTION OF INTERVENTIONAL TRIALS FOR GENE THERAPIES

    Nov 1, 2019, 00:00

  • PMU8 IS PREFERENCE OF ELICITATION TECHNIQUE BASED ON THE DISEASE AREA BEING STUDIED?

    Nov 1, 2019, 00:00

  • PRO65 VARIABILITY IN AGE AT LOSS OF AMBULATION BY GENOTYPE AMONG BOYS WITH DUCHENNE MUSCULAR DYSTROPHY

    Nov 1, 2019, 00:00

  • Personalized Precision Medicine - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PCN215 COST COMPARISON OF LENALIDOMIDE BASED TRIPLE COMBINATION THERAPIES FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PCN6 EVALUATING THE QUALITY AND RISK OF BIAS IN OVERALL SURVIVAL OUTCOMES FROM NON-RANDOMISED CAR T-CELL THERAPY PIVOTAL TRIALS

    Nov 1, 2019, 00:00

  • PNS151 THE ROLE OF REGULATORY GUIDANCE AND INFORMATION DISSEMINATION FOR BIOSIMILAR MEDICINES - THE PERSPECTIVE OF HEALTHCARE PROFESSIONALS AND INDUSTRY

    Nov 1, 2019, 00:00

  • PCN230 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE NEOADJUVANT TREATMENT OF HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN CHINA

    Nov 1, 2019, 00:00

  • PCN192 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN GREECE

    Nov 1, 2019, 00:00

  • PNS353 PRICING AND MARKET ACCESS LAUNCH EXCELLENCE: WHAT ARE THE KEY CHALLENGES FACING COMPANIES TODAY?

    Nov 1, 2019, 00:00

  • PDB99 UNDERSTANDING THE HUMANISTIC BURDEN AND PATIENT IMPACT IN NON-ALCOHOLIC STEATOHEPATITIS (NASH)

    Nov 1, 2019, 00:00

  • PRO49 ANNUAL COST OF TREATMENT OF SPINAL MUSCULAR ATROPHU PATIENTS IN TURKEY

    Nov 1, 2019, 00:00

  • PRO37 HEALTHCARE RESOURCE USE IN CHARCOT-MARIE-TOOTH DISEASE IN THE EU AND US: INTERIM RESULTS FROM AN INTERNATIONAL DIGITAL REAL-WORLD STUDY

    Nov 1, 2019, 00:00

  • PIT6 MEASURING PROMS OF REHABILITATION WITH COMPUTER ADAPTIVE TESTING (CAT) AFTER AN OPERATIVE INTERVENTION OF AN EXTREMITY FRACTURE

    Nov 1, 2019, 00:00

  • PSY27 AN EXAMINATION OF THE BURDEN OF SICKLE CELL DISEASE AMONG ADULTS IN ENGLAND

    Nov 1, 2019, 00:00

  • Reimbursement Access Policy Research

    Nov 1, 2019, 00:00

  • PDB51 PREVENTION AS A PUBLIC HEALTH MEASURE: LONG-TERM EFFECTIVENESS AND COST EFFECTIVENESS OF A POPULATION-BASED IODINE DEFICIENCY DISEASES PREVENTION PROGRAM

    Nov 1, 2019, 00:00

  • PBI42 ANALYSIS OF GENE AND CELL THERAPIES POLICIES IN EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PPM3 GENOMIC SCREENING COSTS IN MODELLING: A PENALTY FOR INNOVATION?

    Nov 1, 2019, 00:00

  • PIN34 A PUBLIC HEALTH AND BUDGET IMPACT ANALYSIS (BIA) OF VACCINATING CHILDREN AGAINST PNEUMOCOCCAL-DISEASES IN AUSTRIA

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PMU55 HURDLES TO REGULATORY AND ACCESS (PRICING AND REIMBURSEMENT) OF 3D-PRINTED TUMOR ASSAYS FOR PERSONALIZED MEDICINE IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PNS254 INCLUSION OF PRODUCTIVITY LOSSES IN HTA ASSESSMENTS IN FUNCTION OF WHO BEARS PRODUCTIVITY LOSSES IN THE REAL WORLD - A QUALITATIVE ASSESSMENT

    Nov 1, 2019, 00:00

  • PNS334 SCIENTIFIC MISCONDUCT AND SYSTEMATIC LITERATURE REVIEWS (SLRS): THE IMPACT OF FRAUDULENT CLINICAL STUDIES ON EVIDENCE-BASED MEDICINE

    Nov 1, 2019, 00:00

  • PIN97 ANTIMICROBIAL UTILIZATION AND INFECTION CAUSED BY GRAM-NEGATIVE BACTERIA IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES IN JAPAN: A MULTI-CENTRE CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PSS19 HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, AND ASSOCIATED FINANCIAL BURDEN AMONG ADULTS WITH PSORIASIS

    Nov 1, 2019, 00:00

  • Neurological Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCN396 CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-TS): ARE ONGOING CLINICAL TRIALS DESIGNED TO MEET EVIDENCE NEEDS OF KEY EUROPEAN HEALTH TECHNOLOGY ASSESSMENT BODIES (HTABS)?

    Nov 1, 2019, 00:00

  • PRS38 PREVALENCE OF SEVERE ASTHMA IN PORTUGAL: RESULTS FROM A PHYSICIANS SURVEY

    Nov 1, 2019, 00:00

  • PRO42 THE CLINICAL, HUMANISTIC AND ECONOMIC BURDEN OF BRONCHIOLITIS OBLITERANS SYNDROME IN EUROPE

    Nov 1, 2019, 00:00

  • PIN28 COST EFFECTIVENESS ANALYSIS OF BACILLUS CALMETTE-GUÉRIN VACCINATION IN INDONESIA

    Nov 1, 2019, 00:00

  • Cancer - Economic Evaluation

    Nov 1, 2019, 00:00

  • PMH4 ASSESSMENT OF QUALITY OF LIFE AMONGST PATIENTS DEPRESCRIBED WITH BENZODIAZEPINES

    Nov 1, 2019, 00:00

  • PDB23 SWITCHING TO INSULIN DEGLUDEC IS A COST-SAVING THERAPY FOR PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES IN THE SWEDISH SETTING BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PDB6 LONG-TERM ASSOCIATION OF OBSERVED VERSUS PREDICTED MICRO- AND MACROVASCULAR COMPLICATIONS IN TYPE 1 DIABETES MELLITUS: EXTERNAL VALIDATION OF THE CORNERSTONE DIABETES SIMULATION MODEL (CDSM)

    Nov 1, 2019, 00:00

  • PNS351 ROLE OF MARKET ACCESS (MA), AND HEALTH ECONOMIC AND OUTCOMES RESEARCH (HEOR) PROFESSIONALS IN THE UPTAKE OF PHARMACEUTICAL PRODUCTS.

    Nov 1, 2019, 00:00

  • PBI87 REAL-WORLD GOLIMUMAB EFFECTIVENESS AND IMPACT ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS OR AXIAL SPONDYLARTHRITIS AND A TREATMENT FAILURE TO PREVIOUS TNFΑ INHIBITOR THERAPY

    Nov 1, 2019, 00:00

  • PCN172 COST-EFFECTIVENESS OF CRC FRENCH SCREENING PROGRAMME FOR AVERAGE RISK INDIVIDUALS

    Nov 1, 2019, 00:00

  • PIN129 ANALYSIS OF THE RELATIONSHIP BETWEEN HEALTH TECHNOLOGY ASSESSMENT (HTA) EVALUATION AND REIMBURSED PRICE OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) COMBINATION DRUGS IN EU-3 (FRANCE, GERMANY, UNITED KINGDOM [UK])

    Nov 1, 2019, 00:00

  • PCV64 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF CARDIAC ARREST IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PCN525 FIRST VALUE-BASED PRICE AGREEMENT IN FRANCE BASED ON PRM REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PMS70 PSYCHOLOGICAL SYMPTOMS AND TOTAL KNEE REPLACEMENT.

    Nov 1, 2019, 00:00

  • PCV55 COST-EFFECTIVENESS OF WARFARIN CARE BUNDLES AND NOVEL ORAL ANTICOAGULANTS FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION IN THAILAND

    Nov 1, 2019, 00:00

  • PCN447 NEW METHODOLOGY IN PARAMETRIC NETWORK META-ANALYSIS: NON-MIXTURE CURE MODELS

    Nov 1, 2019, 00:00

  • Medical Devices - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS315 ON THE USE OF DISCOUNT RATES IN ONE-WAY SENSITIVITY ANALYSIS

    Nov 1, 2019, 00:00

  • PCN342 THE UPTAKE AND IMPACT OF THE EQ-5D-5L VALUE SET IN NICE TECHNOLOGY APPRAISALS WITHIN ONCOLOGY

    Nov 1, 2019, 00:00

  • PNS322 REVIEW OF METHODOLOGICAL APPROACHES TO ANALYSE LONGITUDINAL UTILITY DATA

    Nov 1, 2019, 00:00

  • PND96 COMPARISON OF PROPENSITY SCORE METHODS A CASE STUDY OF DIRECT ORAL ANTICOAGULANTS

    Nov 1, 2019, 00:00

  • PMU54 A 10-YEAR REVIEW (2009-2018) OF MARKET ACCESS OF PHARMACEUTICALS IN THE EU5 AND US

    Nov 1, 2019, 00:00

  • PNS411 ASSESSMENT OF THE ACTIVITY OF PHARMACISTS IN ENSURING THE SAFE USE OF MEDICINES IN UKRAINE

    Nov 1, 2019, 00:00

  • PCN359 VALUE ASSESSMENT OF HTA DECISIONS FOR PD-1/PD-L1 INHIBITORS IN ONCOLOGY: A NICE PERSPECTIVE

    Nov 1, 2019, 00:00

  • Personalized Precision Medicine - Patient-Centered Research

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PNS414 COMPARISON OF THREE LARGE REAL-WORLD DATABASES FROM THREE DIFFERENT COUNTRIES AND IMPLICATIONS FOR THEIR USE FOR RETROSPECTIVE STUDIES

    Nov 1, 2019, 00:00

  • PCN428 SCALABLE PREDICTION OF CANCER PATIENT CLINICAL EVENTS IN REAL WORLD CLINICAL SETTINGS

    Nov 1, 2019, 00:00

  • PIN29 PUBLIC HEALTH AND ECONOMIC IMPACT OF VACCINATION OF SENIORS WITH A HIGH DOSE TRIVALENT INFLUENZA VACCINE IN BRAZILIAN PRIVATE HEALTH CARE SYSTEM

    Nov 1, 2019, 00:00

  • ON4 THE ECONOMIC BURDEN OF RENAL CELL CARCINOMA (RCC) IN CANADA USING REAL-WORLD EVIDENCE; A SOCIETAL PERSPECTIVE.

    Nov 1, 2019, 00:00

  • PNS234 INTERNATIONAL HTA FRAMEWORKS AS ROADMAP TO REVISIT PHARMA ORGANISATION AND OPERATIONS

    Nov 1, 2019, 00:00

  • PND28 THE ECONOMIC BURDEN OF MULTIPLE SCLEROSIS DEVELOPMENT OVER TIME: AN ANALYSIS FROM THE MULTIPLE SCLEROSIS CENTERS PERSPECTIVE

    Nov 1, 2019, 00:00

  • PRS64 CONTENT VALIDATION OF THE RESPIRATORY SYMPTOMS SUBSCALE (RSS) OF THE QUALITY OF LIFE QUESTIONNAIRE-BRONCHIECTASIS (QOL-B) IN NON-CYSTIC FIBROSIS BRONCHIECTASIS (NON-CF BE)

    Nov 1, 2019, 00:00

  • PCN23 UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00

  • PCN44 COMPARATIVE EFFECTIVENESS OF EARLY VS. LATE USE OF SORAFENIB IN INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN

    Nov 1, 2019, 00:00

  • PDB108 THE UNMET MEDICAL NEEDS IN CURRENT ANTIDIABETIC INJECTABLE THERAPY (AIT) IN CHINA: FROM THE PERSPECTIVE OF HEALTHCARE PROVIDERS (HCPS)

    Nov 1, 2019, 00:00

  • PCN493 PERCEPTIONS OF AND PARTICIPATION IN REAL-WORLD EVIDENCE RESEARCH AMONG US COMMUNITY ONCOLOGISTS

    Nov 1, 2019, 00:00

  • PSY5 COST-UTILITY OF TOFACITINIB FOR THE TREATMENT OF SEVERE TO MODERATE RHEUMATOID ARTHRITIS IN PORTUGAL

    Nov 1, 2019, 00:00

  • Mental Health - Medical Technologies

    Nov 1, 2019, 00:00

  • PCN529 BURDEN OF ILLNESS IN NEW OSTOMATES: AN ANALYSIS BASED ON GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PMU93 ASSESSING THE OUTCOMES FOR ORPHAN STATUS OR ACCELERATED ASSESSMENT EMA APPROVED MEDICINES: A COMPARISON OF HEALTH TECHNOLOGY ASSESSMENT IN DENMARK, FINLAND, NORWAY AND SWEDEN

    Nov 1, 2019, 00:00

  • PNS222 NEEDS AND RISKS ASSESSMENT IN CREATION OF HTA-INFORMED HEALTH CARE DECISION-MAKING ECOSYSTEM IN UKRAINE

    Nov 1, 2019, 00:00

  • PCV146 CHARACTERIZATION OF PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL: A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)

    Nov 1, 2019, 00:00

  • PCV63 WHAT'S THE COST OF HOSPITALISATIONS DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION IN THE UNITED STATES?

    Nov 1, 2019, 00:00

  • PCN221 HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN FOUR EUROPEAN COUNTRIES: FINDINGS FROM PREAMBLE

    Nov 1, 2019, 00:00

  • PCV136 PATIENT PREFERENCES FOR MITRAL VALVE PROCEDURE-ASSOCIATED BENEFITS REVEAL GREATER RISK TOLERANCE AS HEART FAILURE SYMPTOMS WORSEN

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PMU80 DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN

    Nov 1, 2019, 00:00

  • PIN16 COST-EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM + METRONIDAZOLE AS A FIRST-LINE TREATMENT IN PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS IN TAIWAN

    Nov 1, 2019, 00:00

  • PDB73 RELATIONSHIP BETWEEN METABOLIC SYNDROME RISK LEVEL, BODY COMPOSITION AND LIPID PROFILE AMONG ADULTS IN MONGOLIA

    Nov 1, 2019, 00:00

  • PND129 BAD WEATHER CAUSES MIGRAINE? ASSOCIATION BETWEEN METEOROLOGICAL VARIABLES, HEADACHES AND MIGRAINE USING GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PCV129 SELF-ASSESSED FUNCTIONAL INSTRUMENT IN HEART FAILURE: CORRELATION WITH PATIENT REPORTED SYMPTOMS

    Nov 1, 2019, 00:00

  • Drugs Generics - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PMU51 BARRIERS AGAINST PROGRAMS FOR THE PREVENTION OF IODINE DEFICIENCY DISORDERS IN EUROPE: A DELPHI STUDY

    Nov 1, 2019, 00:00

  • PCN273 EPIDEMIOLOGY AND UNMET NEEDS OF BLADDER CANCER IN ITALY

    Nov 1, 2019, 00:00

  • PCV29 COST-EFFECTIVENESS OF CORONARY AND PERIPHERAL ARTERY DISEASE TREATMENTS

    Nov 1, 2019, 00:00

  • PNS272 AMNOG BENEFIT ASSESSMENT IN GERMANY AND ITS IMPACT ON PRICE NEGOTIATIONS

    Nov 1, 2019, 00:00

  • PCN76 A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCN89 COST-EFFECTIVENESS OF NIVOLUMAB AS ADJUVANT TREATMENT OF MELANOMA IN ADULTS WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN BELGIUM

    Nov 1, 2019, 00:00

  • PNS42 TO WHAT EXTENT DOES SEEKING CLINICAL EXPERT OPINION FOR MODEL INPUTS REDUCE THE COST OF UNCERTAINTY? A CONCEPTUAL APPROACH USING EXPECTED VALUE OF PERFECT PARAMETER INFORMATION (EVPPI)

    Nov 1, 2019, 00:00

  • PND2 INDIRECT COMPARISON OF THE EFFICACY OF FREMANEZUMAB VERSUS ERENUMAB IN EPISODIC MIGRAINE PATIENTS WHO HAD FAILED 2-4 PRIOR MIGRAINE PREVENTIVE TREATMENTS

    Nov 1, 2019, 00:00

  • PND116 QUALITATIVE CONCEPT ELICITATION INTERVIEWS TO UNDERSTAND THE PATIENT EXPERIENCE OF GLUCOCEREBROSIDASE-PARKINSON'S DISEASE (GBA-PD)

    Nov 1, 2019, 00:00

  • PNS23 THE IMPACT OF EARLY CENSORING ON THE PFS BY A MULTI-STATE MODEL

    Nov 1, 2019, 00:00

  • PMS41 PROJECTION OF THE PREVALENCE OF RHEUMATIC DISEASES IN PORTUGAL THROUGH THE FIRST HALF OF THE 21ST CENTURY

    Nov 1, 2019, 00:00

  • PMU141 DEVELOPMENT OF EQ-5D-5L BOLT-ONS FOR COGNITION AND VISION

    Nov 1, 2019, 00:00

  • PMD26 THE ECONOMIC EVALUATION OF THE SFLT-1/PIGF RATIO IN THE PREDICTION OF PRE-ECLAMPSIA

    Nov 1, 2019, 00:00

  • PMD39 HOSPITAL REIMBURSEMENT PATHWAYS FOR NEW EXAMINATION AND TREATMENT METHODS IN GERMANY

    Nov 1, 2019, 00:00

  • PMU144 DISEASE STATE ADAPTATION AND ESTIMATES OF QUALITY-OF-LIFE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN449 AN ANALYSIS OF EQ-5D ADJUSTING FOR TREATMENT SWITCHING: THE CASE OF PATIENTS WITH EGFR T790M POSITIVE NSCLC TREATED WITH OSIMERTINIB

    Nov 1, 2019, 00:00

  • PNS227 THE NOT-NICE ACCESS PATHWAY: NHS ENGLAND SPECIALISED COMMISSIONING

    Nov 1, 2019, 00:00

  • PIH17 COST-EFFECTIVENESS OF INTERVENTIONS PREVENTING FALLS IN OLDER ADULTS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PIN116 THE BURDEN OF INFLUENZA POSITIVE INPATIENTS IN TURKEY

    Nov 1, 2019, 00:00

  • PCN402 THE CLINICAL AND ECONOMIC CONSEQUENCES OF DELAYS IN REIMBURSEMENT FOR SELECT NOVEL CANCER THERAPEUTICS IN CANADA, ITALY, AND AUSTRALIA

    Nov 1, 2019, 00:00

  • PNS356 PAYERS RELATED ISSUES ARISING FROM THE DEVELOPMENT OF PHARMACEUTICAL PRODUCTS AT PRE-LAUNCH

    Nov 1, 2019, 00:00

  • PRO24 COST-EFFECTIVENESS ANALYSIS OF PROPHYLAXIS VS. ON-DEMAND TREATMENT FOR HAEMOPHILIA B CHILDREN WITHOUT INHIBITOR IN CHINA

    Nov 1, 2019, 00:00

  • PNS331 QUANTIFYING THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES USING THE EQ-5D-3L INSTRUMENT

    Nov 1, 2019, 00:00

  • PIN21 THE ECONOMIC IMPACT OF TRICLOSAN-COATED SUTURES IN WOUND CLOSURE: A BUDGET IMPACT ANALYSIS FROM HOSPITAL PERSPECTIVE IN ITALY

    Nov 1, 2019, 00:00

  • PND71 EPIDEMIOLOGY OF ATTENTION DEFICIT HYPERACTIVITY DISORDERS IN SPAIN BASED ON REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PNS258 ABBREVIATED HTA PATHWAYS, EXPEDITING PATIENT ACCESS TO NOVEL TREATMENTS?

    Nov 1, 2019, 00:00

  • PNS45 ADDING NOISE TO MARKOV COHORT MODELS

    Nov 1, 2019, 00:00

  • PRO110 A STRUCTURED REVIEW OF NICE AND SMC APPRAISALS IN ORPHAN GENETIC NEUROLOGICAL DISEASES: ECONOMIC AND CLINICAL UNCERTAINTIES AND HOW TO ADDRESS THEM

    Nov 1, 2019, 00:00

  • PRO75 PATIENT ACCESS TO ORPHAN MEDICINES IN TURKEY

    Nov 1, 2019, 00:00

  • PRS4 SABA OVERUSE AND HEALTH CARE RESOURCE UTILIZATION IN A NATIONWIDE SWEDISH ASTHMA COHORT (HERA)

    Nov 1, 2019, 00:00

  • PGI59 INCREASED AVAILABILITY OF REIMBURSED INTERFERON-FREE TREATMENTS FOR HCV IN POLAND AND ITS COST

    Nov 1, 2019, 00:00

  • PCN33 ADJUSTED COMPARISON OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS LENALIDOMIDE PLUS DEXAMETHASONE (RD) IN SECOND LINE (2L) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS, USING INDIVIDUAL PATIENT LEVEL DATA (IPD) ...

    Nov 1, 2019, 00:00

  • PDB24 REAL WORLD DATA ANALYSIS OF HEALTHCARE RESOURCE USE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE

    Nov 1, 2019, 00:00

  • PMD49 MECHANICAL COMPLICATIONS ASSOCIATED WITH INTRAMEDULLARY NAILING FOR TROCHANTERIC, INTERTROCHANTERIC AND SUBTROCHANTERIC FEMUR FRACTURES

    Nov 1, 2019, 00:00

  • PRS68 A RETROSPECTIVE DATABASE STUDY OF A CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION PATIENT COHORT TO EVALUATE THE PATIENT CHARACTERISTICS AND ECONOMIC BURDEN OF ILLNESS IN ENGLAND

    Nov 1, 2019, 00:00

  • PIN149 RETROSPECTIVE SURVEY FOR HEPATITIS B VIRUS REACTIVATION DURING IMMUNOSUPPRESSIVE THERAPIES FOR RHEUMATOID WITH ADMINISTRATIVE DATA

    Nov 1, 2019, 00:00

  • PRO15 ORPHAN DRUG METHODOLOGY CHALLENGES IN THE DANISH HTA PROCESS - MEDICINRAADET AND THE HURDLES TO SHOWING CLINICAL BENEFIT IN SMALL PATIENT POPULATIONS

    Nov 1, 2019, 00:00

  • PCN90 MANAGEMENT AND COST OF FEBRILE NEUTROPENIA (FN) IN THE ONCOLOGY PATIENT

    Nov 1, 2019, 00:00

  • PSU14 HEALTHCARE BURDEN OF SURGICAL SITE INFECTIONS FOLLOWING CORONARY ARTERY BYPASS GRAFT SURGERY

    Nov 1, 2019, 00:00

  • Methodological and Conceptual Studies

    Nov 1, 2019, 00:00

  • PBI48 EQUALITY IN ACCESS TO DMARDS IN TURKEY

    Nov 1, 2019, 00:00

  • PCV74 COST-EFFECTIVENESS OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE

    Nov 1, 2019, 00:00

  • PUK16 COST-UTILITY ANALYSIS OF MIRABEGRON VERSUS ANTIMUSCARINIC THERAPY IN THE TREATMENT OF OVERACTIVE BLADDER

    Nov 1, 2019, 00:00

  • PMD10 INSIGHTS INTO THE IMPACT OF POINT-OF-CARE TESTING: A SYSTEMATIC REVIEW OF HEALTH-ECONOMIC EVALUATIONS

    Nov 1, 2019, 00:00

  • PCN365 TITLE: REVIEW OF PUBLISHED EFFICIENCY OPINIONS OF THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP) IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PNS249 HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENTS IN EUROPE AND NORTH AMERICA SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PIH62 INVESTIGATING THE RESPONSIVENESS TO CHANGE OF THE HIV TREATMENT SATISFACTION QUESTIONNAIRE CHANGE VERSION (HIVTSQC) IN OVERCOMING CEILING EFFECTS IN THE HIV TREATMENT SATISFACTION QUESTIONNAIRE STATUS VERSION (HIVTSQS)

    Nov 1, 2019, 00:00

  • PMU145 SYSTEMATIC REVIEW OF PAEDIATRIC ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: DONOR AVAILABILITY, QUALITY OF LIFE AND ECONOMIC IMPLICATIONS

    Nov 1, 2019, 00:00

  • PCN220 COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • ND3 SHORT- AND LONG-TERM DISABILITY BURDEN AMONG EMPLOYED PATIENTS RECEIVING DISEASE-MODIFYING TREATMENT FOR MULTIPLE SCLEROSIS

    Nov 1, 2019, 00:00

  • PRO5 COMPARING PRODUCTIVITY LOSSES FROM TREATING ATYPICAL HEMOLYTIC UREMIC SYNDROME PATIENTS IN THE UNITED STATES WITH ECULIZUMAB OR RAVULIZUMAB IN AN INFUSION CLINIC OR AT HOME

    Nov 1, 2019, 00:00

  • PND89 NEGATIVE HTA RECOMMENDATIONS FOR MEDICINES IN NEUROLOGY THERAPEUTIC AREAS – FOURFOLD HIGHER ODDS IN POLAND COMPARED WITH THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PCN381 KEY FACTORS FOR THE CONSIDERATION OF QUALITY OF LIFE DATA IN AMNOG BENEFIT ASSESSMENTS

    Nov 1, 2019, 00:00

  • PSU8 COMPARING COSTS OF USING FIBRINOGEN CONCENTRATE VERSUS FRESH FROZEN PLASMA IN THE TREATMENT OF BLEEDING DURING CARDIAC SURGERY IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PCN217 COST-EFFECTIVENESS OF LENVATINIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN THE UK

    Nov 1, 2019, 00:00

  • Neurological Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCN169 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE

    Nov 1, 2019, 00:00

  • PIH39 EVALUATION OF PROPRANOLOL OFF-LABEL USE IN INFANTILE HEMANGIOMA AND EFFECTIVENESS OF RISK MINIMISATION MEASURES TO MITIGATE ADVERSE REACTIONS: A FRENCH AND GERMAN DRUG UTILIZATION STUDY

    Nov 1, 2019, 00:00

  • PDB11 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS): TOTAL COSTS

    Nov 1, 2019, 00:00

  • PRS55 PREDICTING THE RISK OF IN-HOSPITAL MORTALITY IN ADULT COMMUNITY-ACQUIRED PNEUMONIA PATIENTS WITH MACHINE LEARNING: A RETROSPECTIVE ANALYSIS OF ROUTINELY COLLECTED HEALTH DATA

    Nov 1, 2019, 00:00

  • PDG68 USE OF ANTICANCER DRUGS IN IVORY COAST FROM 2017 TO 2018

    Nov 1, 2019, 00:00

  • PMU94 DATA GENERATED BY THE FRENCH COMPASSIONATE USE PROGRAM: HOW CAN THEY CONTRIBUTE TO THE HEALTH TECHNOLOGY ASSESSMENT?

    Nov 1, 2019, 00:00

  • PCN433 DISCRETE TIME RESTRICTED CUBIC SPLINE MODELS FOR NETWORK META-ANALYSIS OF TIME-TO-EVENT OUTCOMES

    Nov 1, 2019, 00:00

  • PCN137 COST COMPARISON OF ADVERSE EVENTS AND TREATMENT ADMINISTRATION OF LURBINECTEDIN VERSUS INTRAVENOUS TOPOTECAN FOR RELAPSED SMALL CELL LUNG CANCER IN SPAIN AND THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PCV143 SACUBITRIL/VALSARTAN PRESCRIPTION PATTERNS AND TITRATION IN A REAL-WORLD SETTING IN PORTUGAL: AN ANALYSIS OF THE PRIME STUDY

    Nov 1, 2019, 00:00

  • PCV40 COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN

    Nov 1, 2019, 00:00

  • PMU151 ECONOMIC BURDEN OF BIOSIMILAR DELIVERY IN FRANCE: REAL WORLD ANALYSIS FROM THE PERMANENT SAMPLE OF NATIONAL HEALTH INSURANCE BENEFICIARIES, BETWEEN 2007 TO 2017

    Nov 1, 2019, 00:00

  • RW4 APPLICATION OF ARTIFICIAL INTELLIGENCE AND MEDICAL BIG-DATA IN REAL WORLD EVIDENCE GENERATION: A LITERATURE REVIEW OF RESEARCH PRACTICE IN CHINA

    Nov 1, 2019, 00:00

  • PND30 THE SOCIETAL IMPACT OF ERENUMAB IN PROPHYLACTIC TREATMENT OF PATIENTS WITH MIGRAINE IN GERMANY: A MACROECONOMIC OPEN-COHORT APPROACH

    Nov 1, 2019, 00:00

  • PNS129 NET PRICES OF GENERICS IN GREECE DUE TO PAYBACKS: UPDATING THE FACTS

    Nov 1, 2019, 00:00

  • PNS64 DOES IT WORTH TO INVEST ON INTRAOPERATIVE HYPOTHERMIA PREVENTION? - HYBRID EVIDENCES FROM META-ANALYSES AND COST-BENEFIT ANALYSIS

    Nov 1, 2019, 00:00

  • PSS9 DRUG UTILIZATION AND COSTS OF INTRAVITREAL INJECTED ANTIVEGFS IN ITALY

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PND82 A DELPHI PANEL ON TREATMENT OF HIGH DISEASE ACTIVITY RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PNS196 EXPERIENCES WITH SUPPLEMENTARY HEALTH INSURANCE POLICIES IN HUNGARY AND OTHER EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PMH44 INCREASED USE OF AUGMENTATION THERAPIES ILLUSTRATES COMPLEX MANAGEMENT OF TREATMENT RESISTANT DEPRESSION. PRELIMINARY RESULTS FROM A REAL-WORD EVIDENCE REGISTRY IN EUROPE, THE 54135419DEP4001 STUDY

    Nov 1, 2019, 00:00

  • PMS8 RATE OF FRACTURES LEADING TO HOSPITALISATION AND HEALTHCARE BURDEN IN UNTREATED OSTEOPOROSIS ELDERLY PATIENTS IN GERMANY: AN INGEF HEALTHCARE INSURANCE DATABASE ANALYSIS

    Nov 1, 2019, 00:00

  • PRO114 EQ-5D UTILITY ESTIMATES FOR PATIENTS WITH SYSTEMIC SCLEROSIS (SSC). INSIGHTS FROM THE FOCUSSCED PHASE III EFFICAY AND SAFETY STUDY OF TOCILIZUMAB.

    Nov 1, 2019, 00:00

  • PBI66 ARE HTA AGENCIES BUYING INTO THE CAR-T HYPE?

    Nov 1, 2019, 00:00

  • PDG64 TRENDS IN THE USE OF LIPID-LOWERING DRUGS IN IVORY COAST (2017-2018)

    Nov 1, 2019, 00:00

  • PAM13 IMPACT ON CARERS OF ADULT PATIENTS RECEIVING PARENTERAL SUPPORT FOR SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE

    Nov 1, 2019, 00:00

  • PNS80 COST-EFFECTIVENESS ANALYSES OF PERSONALISATION/HOME CARE FOR OLDER PEOPLE COMPARED TO NURSING HOME CARE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PND37 10-YEAR COST-EFFECTIVENESS ANALYSES OF RESPONSE-BASED USE OF FREMANEZUMAB AS PREVENTIVE TREATMENT IN CHRONIC AND EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS

    Nov 1, 2019, 00:00

  • PMS71 THE BURDEN OF CONTROLLED AND UNCONTROLLED GOUT: AN ANALYSIS OF PATIENT-REPORTED OUTCOMES IN THE EUROPEAN UNION FIVE (FRANCE, GERMANY, ITALY, SPAIN, UNITED KINGDOM)

    Nov 1, 2019, 00:00

  • PCN441 NEW METHODOLOGY IN NETWORK META-ANALYSIS USING MIXTURE CURE MODELS

    Nov 1, 2019, 00:00

  • PNS36 A CONCEPTUAL PAPER ON THE USE OF PATIENT SUPPORT PROGRAMS IN PROVIDING BETTER ACCESS TO MEDICAL CARE IN EGYPT

    Nov 1, 2019, 00:00

  • PDG48 AN ANALYSIS OF THE DANISH MODEL FOR ANALOGUE COMPETITION OF HOSPITAL MEDICINE BASED ON THE THERAPEUTIC AREA, HEPATITIS C

    Nov 1, 2019, 00:00

  • PNS119 PHARMACEUTICAL POLICY REFORM UNDER SOCIAL HEALTH INSURANCE IN INDONESIA: DOES ACCESS TO QUALIFIED MEDICINE GET BETTER?

    Nov 1, 2019, 00:00

  • PSS6 WHAT IS THE LIFETIME COST OF BLINDNESS IN PEOPLE WITH RPE65-MEDIATED INHERITED RETINAL DYSTROPHY IN THE UK?

    Nov 1, 2019, 00:00

  • PDB50 DOES THE APPLICATION OF UKPDS RISK EQUATIONS UNDERESTIMATE THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS?

    Nov 1, 2019, 00:00

  • PDG83 PHARMACEUTICAL PRICING: LAUNCH STRATEGY RULES? ANALYSIS OF GERMAN DATA

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PDG87 ARE VALUE ASSESSMENT FRAMEWORKS USING RWE? A REVIEW OF NICE AND ICER PSORIASIS ASSESSMENTS

    Nov 1, 2019, 00:00

  • PMU104 NAVIGATING DIVERGENCE: ACCOMMODATING THE MULTITUDE OF NEW PAYER BODIES IN EMERGING MARKETS

    Nov 1, 2019, 00:00

  • PRS20 INFLUENCE OF COPD SEVERITY AND ITS COMORBIDITIES ON DIRECT AND INDIRECT COSTS: RESULTS FROM THE LQ-DMP STUDY

    Nov 1, 2019, 00:00

  • PCN518 ONCOLOGY REAL WORLD DATA (RWD): ENABLING LEARNING HEALTH SYSTEMS

    Nov 1, 2019, 00:00

  • PBI70 WILL CAR-T CELL THERAPIES CHANGE HOW DRUGS ARE PRICED AND REIMBURSED?

    Nov 1, 2019, 00:00

  • AI2 GEO-SPATIAL RISK ASSESSMENT OF ASTHMA HEALTH RESOURCE USE AT THE MUNICIPAL LEVEL IN THE GREATER HELSINKI METROPOLITAN AREA OF FINLAND

    Nov 1, 2019, 00:00

  • PRO154 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE BRIEF PAIN INVENTORY (BPI-SF) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)

    Nov 1, 2019, 00:00

  • PAM3 INDIVIDUALIZED NUTRITIONAL SUPPORT IN MEDICAL INPATIENTS RESULTS IN COST SAVINGS: ECONOMIC EVALUATION OF THE EFFORT TRIAL

    Nov 1, 2019, 00:00

  • PIN72 A PUBLIC HEALTH AND BUDGET IMPACT ANALYSIS (BIA) OF INFLUENZA VACCINATION IN THE AUSTRIAN POPULATION

    Nov 1, 2019, 00:00

  • PCN30 ROLE OF CAR-T CELLS THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

    Nov 1, 2019, 00:00

  • PCN84 COST OF ILLNESS OF CUTANEOUS SQUAMOUS CELL CARCINOMA IN ITALY

    Nov 1, 2019, 00:00

  • ON6 IMPACT OF THE FOLLICULAR LYMPHOMA (FL) TREATMENT CONTINUUM ON A PATIENTS QUALITY OF LIFE (QOL) IN EUROPE (EU5)

    Nov 1, 2019, 00:00

  • PCN99 THE COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RITUXIMAB(HANLIKANG) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA

    Nov 1, 2019, 00:00

  • PBI21 TREATMENT COSTS OF MATRIX-ASSOCIATED AUTOLOGOUS CHONDROCYTES IMPLANTATION COMPARED TO MICROFRACTURE — RESULTS OF A MATCHED-PAIR CLAIMS DATA ANALYSIS ON TREATMENT OF CARTILAGE KNEE DEFECTS IN GERMANY

    Nov 1, 2019, 00:00

  • PSS23 DISEASE BURDEN IN PATIENTS WITH MILD PSORIASIS: GROUP CONCEPT MAPPING

    Nov 1, 2019, 00:00

  • PNS341 ANALYSIS OF EDUCATION AND TRAINING OPPORTUNITIES IN HE/PE/HTA IN CEE CONSORTIUM COUNTRIES

    Nov 1, 2019, 00:00

  • PSU30 EQUITY OF ACCESS TO MINIMAL INVASIVE SURGERY FOR WOMEN WITH ENDOMETRIAL CANCER

    Nov 1, 2019, 00:00

  • PMD45 A COMPANION APP TO SUPPORT PATIENTS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM A USABILITY STUDY

    Nov 1, 2019, 00:00

  • PNS26 USING SURROGATES FOR PREDICTION OVERALL SURVIVAL IN ONCOLOGY: CONSIDERATIONS FOR NEW TREATMENTS AND EARLIER STAGES OF CANCER

    Nov 1, 2019, 00:00

  • PMS44 FRACTURES OF THE RADIUS IN WOMEN AGED 50 YEARS AND OVER: A STUDY OF ELECTRONIC MEDICAL RECORDS

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PDB21 PREDICTING HEALTHCARE COSTS OF DIABETES USING MACHINE LEARNING MODELS

    Nov 1, 2019, 00:00

  • Cancer - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PIN99 INDIRECT COSTS ASSOCIATED WITH SKIN AND SOFT TISSUE INFECTIONS IN CHILDREN: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PSU21 COST-EFFECTIVENESS OF ENDOSCOPIC SLEEVE GASTROPLASTY FOR WEIGHT LOSS

    Nov 1, 2019, 00:00

  • Personalized Statistical Research

    Nov 1, 2019, 00:00

  • PBI47 PAYER AND PRESCRIBER PERSPECTIVES ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPIES IN DIFFUSE LARGE B-CELL LYMPHOMA

    Nov 1, 2019, 00:00

  • PNS390 EMA/FDA PARALLEL QUALIFICATION PROCEDURE FOR THE DEVELOPMENT OF NOVEL PATIENT REPORTED OUTCOME INSTRUMENTS:PROCESS AND IMPACT

    Nov 1, 2019, 00:00

  • PDB110 THE UNMET MEDICAL NEEDS IN CURRENT ANTIDIABETIC INJECTABLE THERAPY (AIT) IN CHINA: FROM PATIENTS' PERSPECTIVE

    Nov 1, 2019, 00:00

  • Multiple Diseases - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward [Editor's Choice]

    Nov 1, 2019, 00:00

  • PCN237 IMPACT OF ORAL TARGETED THERAPY ON THE ECONOMIC BURDEN OF CLL IN CANADA

    Nov 1, 2019, 00:00

  • Neurological Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PBI49 THE EXPEDITED REGULATORY PROGRAMS FOR REGENERATIVE MEDICINES IN US, EU AND JAPAN

    Nov 1, 2019, 00:00

  • PMH14 THE BURDEN OF TREATMENT-RESISTANT DEPRESSION: A TARGETED LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS232 HTA RESHAPING: REDEFINING THE HEALTH TECHNOLOGY EVALUATION FRAMEWORK IN PORTUGAL

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN210 RESOURCE UTILIZATION AND COST FOR WOMEN WITH ADVANCED HR+/HER2- BREAST CANCER IN COLOMBIAN HEALTH CARE SETTINGS

    Nov 1, 2019, 00:00

  • PBI68 ADDED BENEFIT ASSESSMENT OF ATMPS IN GERMANY: DOES THE DATA BASIS MEET HTA REQUIREMENTS?

    Nov 1, 2019, 00:00

  • PDB46 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS): PRODUCTIVITY LOSS AND INDIRECT COSTS

    Nov 1, 2019, 00:00

  • Mental Health - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN399 ASSESSMENT OF SURROGACY OUTCOMES FOR OVERALL SURVIVAL IN ONCOLOGY BASED ON NICE APPRAISALS AND POST-APPRAISAL EVIDENCE

    Nov 1, 2019, 00:00

  • PIH44 SURGICAL TREATMENT OF PATIENTS NEWLY DIAGNOSED WITH UTERINE FIBROIDS: A CLAIMS-BASED DATA ANALYSIS

    Nov 1, 2019, 00:00

  • PCV135 OBSERVATIONAL, INTERNATIONAL, COHORT STUDY TO EVALUATE THE SATISFACTION AND PREFERENCES OF PATIENTS IN PREVENTIVE TREATMENT OF SECONDARY CARDIOVASCULAR EVENTS WITH A CARDIOVASCULAR POLYPILL

    Nov 1, 2019, 00:00

  • PIH4 SUPPORTING THE CONTENT VALIDITY OF THE MENSTRUAL PICTOGRAM SUPER-ABSORBENT POLYMERS CONTAINING VERSION 3 (MP SAP-C V3) USING DATA FROM COGNITIVE INTERVIEWS (CIS) OF WOMEN WITH UTERINE FIBROIDS (UF)

    Nov 1, 2019, 00:00

  • PSU13 COST UTILITY ANALYSIS OF ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY VERSUS OPEN RADICAL NEPHRECTOMY IN KOREAN PATIENTS WITH RENAL CANCER

    Nov 1, 2019, 00:00

  • PND8 A SYSTEMATIC LITERATURE REVIEW OF EFFICACY AND SAFETY OF DISEASE MODIFYING THERAPIES (DMTS) IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS

    Nov 1, 2019, 00:00

  • PCN519 REAL WORLD EVIDENCE (RWE): ANALYSIS OF THE PROGNOSIS OF PATIENTS WITH METASTATIC COLON CANCER UNDER BIOLOGIC TREATMENT IN THE SOCIAL SECURITY SECTOR OF ARGENTINA

    Nov 1, 2019, 00:00

  • PIN152 ECONOMIC IMPACT OF SEQUELAE RELATED TO INVASIVE MENINGOCOCCAL DISEASE IN A FRENCH REAL-WORLD SETTING

    Nov 1, 2019, 00:00

  • PNS345 BUSINESS MODEL INNOVATION OF INTERNET HOSPITALS IN CHINA: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PIN132 HEALTH-ECONOMIC MODELLING OF INFECTIOUS DISEASE DIAGNOSTICS: CURRENT APPROACHES AND FUTURE OPPORTUNITIES

    Nov 1, 2019, 00:00

  • PDB14 COST-EFFECTIVENESS OF CONTRAVE® IN OBESITY MANAGEMENT IN CANADA

    Nov 1, 2019, 00:00

  • PIT3 PROGNOSTIC FACTORS FOR POOR RECOVERY AFTER TRAUMA: A PROSPECTIVE MULTICENTRE COHORT STUDY

    Nov 1, 2019, 00:00

  • PCV65 FEE FOR SERVICE VERSUS LUMP SUM PAYMENT: COST-COST MODEL FOR RULING OUT CORONARY ARTERY DISEASE IN GERMANY - PRIVATE INSURANCE VERSUS STATUTORY SICK FUNDS

    Nov 1, 2019, 00:00

  • PCN297 ATTRIBUTE DEVELOPMENT FOR A DISCRETE CHOICE EXPERIMENT (DCE) EXPLORING WILLINGNESS TO PAY (WTP) FOR CURING CANCER

    Nov 1, 2019, 00:00

  • PNS31 REIMBURSEMENT IN GERMANY: THE IMPACT OF G-BA RECENTLY REVISED REQUIREMENTS FOR AMNOG DOSSIERS

    Nov 1, 2019, 00:00

  • PSY18 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER ANTI-TUMOUR NECROSIS FACTOR (ANTI-TNF) FAILURE OR INTOLERANCE IN SPAIN

    Nov 1, 2019, 00:00

  • PRS52 DEVELOPMENT OF A NOVEL ECONOMIC MODELING APPROACH FOR ASTHMA

    Nov 1, 2019, 00:00

  • PND97 FACTORS INFLUENCING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS USING EXPAND TRIAL DATA

    Nov 1, 2019, 00:00

  • PRO145 THE HUMANISTIC BURDEN OF SHORT-TERM ADVERSE EVENTS ASSOCIATED WITH THE CHOP CHEMOTHERAPY REGIMEN IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS IN EUROPEAN COUNTRIES: A COMPREHENSIVE LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PIN106 SYSTEMATIC LITERATURE REVIEW OF HERPES ZOSTER INCIDENCE WORLDWIDE

    Nov 1, 2019, 00:00

  • MT3 OUTCOMES AND HOSPITAL UTILIZATION OF SLEEP APNEA PATIENTS TREATED WITH POSITIVE AIRWAY PRESSURE DURING AND AFTER ONSET OF HEART FAILURE

    Nov 1, 2019, 00:00

  • PCN303 ITALIAN NATIONAL HEALTH SERVICE REIMBURSEMENT POLICY FOR ONCOLOGY DRUGS AFTER CONDITIONAL MARKET AUTHORIZATION GRANTED BY THE EUROPEAN MEDICINE AGENCY: A RETROSPECTIVE ANALYSIS

    Nov 1, 2019, 00:00

  • Cancer - Medical Technologies

    Nov 1, 2019, 00:00

  • PND25 SYSTEMATIC LITERATURE REVIEW OF ECONOMIC BURDEN ASSOCIATED WITH MULTIPLE SCLEROSIS

    Nov 1, 2019, 00:00

  • Surgery - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PMU99 REVIEW OF RECENT NICE TECHNOLOGY APPRAISALS USING SIMULATED TREATMENT COMPARISONS

    Nov 1, 2019, 00:00

  • PIN45 A COST-UTILITY ANALYSIS OF SEASONAL QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINE IN TURKEY

    Nov 1, 2019, 00:00

  • PMU27 BUDGET IMPACT ANALYSIS OF IMPLEMENTING THE CLOSED-SYSTEM TRANSFER DEVICE QIMONO® DURING CHEMOTHERAPY ADMINISTRATION IN A FRENCH HOSPITAL

    Nov 1, 2019, 00:00

  • PCN111 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SWITZERLAND

    Nov 1, 2019, 00:00

  • Neurological Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PNS375 FEASIBILITY OF AN ONLINE-ONLY METHOD OF GENERATING SUBJECT USABILITY AND COGNITIVE UNDERSTANDING DATA FOR ELECTRONICALLY ADMINISTERED QUESTIONNAIRES: AN EXAMPLE USING THE TREATMENT SATISFACTIONS QUESTIONNAIRE FOR MEDICATION (TSQM)

    Nov 1, 2019, 00:00

  • PCN70 EVALUATING AN ONLINE CALCULATOR FOR ANALYZING DRUG COSTS OF THERAPY OF METASTATIC BREAST CANCER IN RUSSIAN FEDERATION: A NATIONAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • PIN46 CONTRASTING AVAILABLE THERAPY FOR PATIENTS WITH LIMITED OPTIONS DUE TO EXTREMELY DRUG-RESISTANCE BACTERIA WITH A NOVEL OPTION FOR COMPLICATED NOSOCOMIAL INFECTIONS

    Nov 1, 2019, 00:00

  • PSU19 ROBOTIC ASSISTED GASTRECTOMY COMPARED WITH OPEN RESECTION: A CASE-MATCHED STUDY OF CLINICAL OUTCOMES AND COST-EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PCN82 COST-EFFECTIVENESS OF NIVOLUMAB AS ADJUVANT TREATMENT OF MELANOMA IN ADULTS WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN THE ITALIAN SETTING

    Nov 1, 2019, 00:00

  • PCN347 COMPARISON OF TIME TO REIMBURSEMENT RECOMMENDATIONS OF (ORPHAN-) ONCOLOGY DRUGS IN EUROPE

    Nov 1, 2019, 00:00

  • PCN245 GRADE 3/4 ADVERSE EVENT (AE) COSTS OF NIVOLUMAB VERSUS DABRAFENIB + TRAMETINIB AS ADJUVANT TREATMENT IN PATIENTS WITH STAGE III BRAF-MUTATED CUTANEOUS MELANOMA IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCV38 HEALTH OUTCOMES PROJECTIONS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE IN A REAL-WORLD POPULATION IN PORTUGAL

    Nov 1, 2019, 00:00

  • PRS14 COST-EFECTIVENESS ANALYSIS OF AN INTERVENTION TO REDUCE THE CRITICAL HANDLING ERRORS OF FIXED-DOSE ICS/LABA COMBINATIONS IN ASTHMA PATIENTS IN SPAIN

    Nov 1, 2019, 00:00

  • PRS42 THE ASSOCIATION OF ACUTE RESPIRATORY INFECTIONS WITH METEOROLOGICAL FACTORS AND AIR POLLUTANTS AMONG CHILDREN IN MACAO: A RETROSPECTIVE ANALYSIS BASED ON ARDL APPROACH

    Nov 1, 2019, 00:00

  • PCN179 TREOSULFAN-BASED CONDITIONING VS BUSULFAN-BASED CONDITIONING FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML OR MDS — A UK COST-UTILITY ANALYSIS

    Nov 1, 2019, 00:00

  • PND17 SELECTING APPROPRIATE OUTCOME MEASURES FOR ALS CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • Individual's Health - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PNS203 USE OF DISCRETE CHOICE EXPERIMENTS TO INFORM HTA DECISION MAKING.

    Nov 1, 2019, 00:00

  • PDB122 REAL-WORLD INSULIN THERAPY IN GERMAN TYPE 2 DIABETES MELLITUS PATIENTS: PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND INSULIN DOSAGE

    Nov 1, 2019, 00:00

  • PMS31 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN BIOLOGIC-NAIVE PATIENTS FROM THE PORTUGUESE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PDG108 CLINICAL OUTCOMES ON SWITCHING BETWEEN NEWER P2Y12 RECEPTOR INHIBITORS AND CLOPIDOGREL IN DUAL ANTIPLATELET THERAPY IN HONG KONG ACUTE CORONARY SYNDROME POPULATION USING REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PIH60 PEDIATRIC PATIENT ENGAGEMENT: USING PATIENT INSIGHTS TO IMPROVE STUDY DESIGN

    Nov 1, 2019, 00:00

  • PRO140 KNOWLEDGE, USE AND DESIDERATA ABOUT INFORMATION AND COMMUNICATION TECHNOLOGIES SYSTEMS FOR SYSTEMIC LUPUS ERYTHEMATOSUS. PRELIMINARY RESULTS FROM THE INTEGRATE PILOT PROJECT.

    Nov 1, 2019, 00:00

  • PNS55 THE COST OF MEDICATION ERRORS IN PUBLIC HEALTH FACILITIES OF EASTERN REGION, GHANA.

    Nov 1, 2019, 00:00

  • PCN435 IMPROVED ESTIMATES OF EXTRAPOLATED MEAN SURVIVAL TIMES USING FINITE MIXTURE MODELS: REDUCING UNCERTAINTY IN COST EFFECTIVENESS ANALYSIS

    Nov 1, 2019, 00:00

  • PMU116 NICE MEDICAL TECHNOLOGIES GUIDANCE: IMPACT BEYOND THE UK

    Nov 1, 2019, 00:00

  • PNS307 THE COMBINED USE OF TREEAGE SOFTWARE TO ACCELERATE MARKOV MODEL CONSTRUCTION WITHIN AN EXCEL USER INTERFACE

    Nov 1, 2019, 00:00

  • PRO53 WHAT IS THE RELATIONSHIP BETWEEN PRICE AND PREVALENCE IN NON-ONCOLOGY RARE DISEASE?

    Nov 1, 2019, 00:00

  • PIH65 IMPACT ON CARERS OF PAEDIATRIC PATIENTS RECEIVING PARENTERAL SUPPORT FOR SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE

    Nov 1, 2019, 00:00

  • PMS4 EFFICACY OF RENAL FUNCTION IN PATIENTS WITH EARLY DIABETIC NEPHROPATHY COMPLICATED WITH HYPERURICEMIA.

    Nov 1, 2019, 00:00

  • PRO148 PSYCHOMETRIC EVALUATION OF A MODIFIED VISUAL FUNCTION QUESTIONNAIRE (MVFQ-25) USING DATA FROM A PHASE III OPEN-LABEL RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH INHERITED RETINAL DYSTROPHY CAUSED BY BIALLELIC RPE65 MUTATIONS

    Nov 1, 2019, 00:00

  • PMD9 INTRODUCING BUDGET IMPACT ANALYSIS COMPARING REUSABLE TO SINGLE-USE BRONCHOSCOPES WITHIN A LARGE UK UNIVERSITY HOSPITAL

    Nov 1, 2019, 00:00

  • PIH67 THE CHANGES OF COST FOR PREECLAMPSIA PREGNANCY AFTER THE ANGIOGENIC FACTORS (SFLT-1 AND PLGF) TESTS. PRELIMINARY DATA OF AN ECONOMIC MODEL BASED ON LOCAL RWD.

    Nov 1, 2019, 00:00

  • Multiple Diseases - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN72 COMPARATIVE COST ANALYSIS OF SUBCUTANEOUS TRASTUZUMAB ORIGINATOR (HERCEPTIN®) VS INTRAVENOUS TRASTUZUMAB BIOSIMILAR (KANJINTI) FROM A HOSPITAL PERSPECTIVE IN ITALY

    Nov 1, 2019, 00:00

  • PCN38 IMPACT OF CERVICAL CANCER SCREENING TIME ON SURGICAL OUTCOMES

    Nov 1, 2019, 00:00

  • PCN12 USING CLINICAL DATA STANDARDS TO FACILITATE COMPARISONS OF ACUTE MYELOID LEUKEMIA TREATMENT PATTERNS AND OUTCOMES IN REAL WORLD CLINICAL CARE AND POOLED CLINICAL TRIAL POPULATIONS

    Nov 1, 2019, 00:00

  • PIH24 COST-UTILITY ANALYSIS OF NEWBORN SCREENING PROGRAM BY TANDEM MASS SPECTROMETRY IN JAPAN

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PDB113 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE

    Nov 1, 2019, 00:00

  • PNS157 WHY EMERGENCY ACCESS TO DRUG TECHNOLOGES IN POLAND DOES NOT WORK?

    Nov 1, 2019, 00:00

  • PMH54 IS THE OXCAP-MH CAPABILITY MEASURE A FEASIBLE AND PSYCHOMETRICALLY VALID TOOL FOR THE ROUTINE EVALUATION OF MENTAL HEALTH SERVICES?

    Nov 1, 2019, 00:00

  • PCV114 FEASIBILITY OF USING REAL WORLD EVIDENCE TO INFORM DECISIONS ON CONDUCTING A COST EFFECTIVENESS ANALYSIS: AN EXAMPLE OF STROKE RISK REDUCTION THERAPIES IN ATRIAL FIBRILLATION

    Nov 1, 2019, 00:00

  • PIN151 PATIENTS TREATED FOR HEPATITIS C: AN OBSERVATIONAL STUDY WITH THE FRENCH ADMINISTRATIVE HEALTH CARE DATABASE (SNDS)

    Nov 1, 2019, 00:00

  • PBI41 CHALLENGES AND OPPORTUNITIES FOR THE REIMBURSEMENT OF GENE THERAPIES - STAKEHOLDER INSIGHTS FROM GERMANY, SWEDEN AND THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PCN170 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY

    Nov 1, 2019, 00:00

  • PDB71 ASSOCIATION OF SEVERE HYPOGLYCEMIA WITH ALL-CAUSE MORTALITY AND COMPLICATIONS AMONG PATIENTS WITH DIABETES MELLITUS IN CHINA

    Nov 1, 2019, 00:00

  • PCN466 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN CLINICAL PRACTICE FOR IMMUNE-CHECKPOINT INHIBITORS (ICI)-TREATED PATIENTS: WHAT ARE PATIENTS' EXPERIENCES AND EXPECTATIONS? RESULTS FROM AN ONLINE PATIENT COMMUNITY RESEARCH

    Nov 1, 2019, 00:00

  • PRO150 A SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITY VALUATIONS IN HAEMOPHILIA

    Nov 1, 2019, 00:00

  • PNS74 COST-EFFECTIVENESS AND RETURN-ON-INVESTMENT OF THE DYNAMIC WORK INTERVENTION

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCV72 CLINICAL AND ECONOMIC IMPLICATIONS OF USING NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR NON-VALVULAR ATRIAL FIBRILLATION USING AVAILABLE EVIDENCE FROM REAL-WORLD EXPERIENCE

    Nov 1, 2019, 00:00

  • PIN73 THE POTENTIAL COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INACTIVATED INFLUENZA VACCINE FOR THE PORTUGUESE ELDERLY POPULATION

    Nov 1, 2019, 00:00

  • PND48 BURDEN OF MULTIPLE SCLEROSIS IN GERMANY — A MATCHED COHORT STUDY USING A LARGE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PGI38 ASSESSMENT OF PROPULSIVES CONSUMPTION IN UKRAINE IN COMPARISON WITH OTHER COUNTRIES OF THE WORLD

    Nov 1, 2019, 00:00

  • NO Specific Disease - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PNS337 IMPROVING ON CYCLE CORRECTIONS FOR TIME-HOMOGENEOUS MARKOV MODELS

    Nov 1, 2019, 00:00

  • PCN334 ESTIMATING DIRECT COSTS AND PRODUCTIVITY COSTS ASSOCIATED WITH RAPID INFUSION OF DARATUMUMAB

    Nov 1, 2019, 00:00

  • PCN225 TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREA ...

    Nov 1, 2019, 00:00

  • PRO122 ECONOMIC EVALUATION OF NUSINERSEN IN SPINAL MUSCULAR ATROPHY: A COMPARISON OF NICE AND HAS OPINIONS

    Nov 1, 2019, 00:00

  • PRO22 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND ECONOMIC BURDEN OF DUCHENNE MUSCULAR DYSTROPHY (DMD): A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • Neurological Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PND122 HEALTHCARE RESOURCE UTILIZATIONS AND COSTS AMONG PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS - A COMPARISON OF PATIENTS WITH AND WITHOUT UPPER LIMB FUNCTION IMPAIRMENT

    Nov 1, 2019, 00:00

  • PIN127 BIRTH COHORT SCREENING FOR HEPATITIS C: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS

    Nov 1, 2019, 00:00

  • PCN77 COST-UTILITY, COST-EFFECTIVENESS, AND BUDGET IMPACT OF INTERNET-BASED COGNITIVE BEHAVIOURAL THERAPY FOR BREAST CANCER SURVIVORS WITH TREATMENT-INDUCED MENOPAUSAL SYMPTOMS

    Nov 1, 2019, 00:00
  • «
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56 (current)
  • 57
  • 58
  • 59
  • 60
  • »